• Corpus ID: 46370969

Monitoring Of Blood L-DOPA And L-DOPA Metabolite Concentrations And Adverse Events In Patients With Advanced Parkinsons Disease Receiving L-DOPA And Amantadine Combination Therapy: A Clinical Study

  title={Monitoring Of Blood L-DOPA And L-DOPA Metabolite Concentrations And Adverse Events In Patients With Advanced Parkinsons Disease Receiving L-DOPA And Amantadine Combination Therapy: A Clinical Study},
  author={Mitsutoshi Satoh and Ami Kuzuu and Hirokazu Doi and Toru Masaka and Ryuji Sakakibara},
  journal={Research \& Reviews: Journal of Pharmacy and Pharmaceutical Sciences},
As L-DOPA replacement is the main treatment for patients with Parkinson’s disease, monitoring of the blood dopamine (DA) concentration is useful for prediction of peripheral adverse events. We studied patients with advanced Parkinson’s disease for whom L-DOPA and an NMDA receptor antagonist, amantadine, had been prescribed since 2006 at Sakura Hospital, Toho University Medical Center. The blood concentrations of L-DOPA, DA, 3,4-dihydroxyphenylacetic acid (DOPAC) and 3-O-methyldopa (3-OMD… 
2 Citations

Figures and Tables from this paper

A G-Protein Coupled Receptor and Macular Degeneration
The convergence of factors related to race, pigmentation, and susceptibility to AMD, where the primary defect occurs in retinal support cells, is discussed, including whether the downstream signaling activity of GPR143, a G-protein coupled receptor in the pigmentation pathway, might underly the racial bias of AMD and be a target to prevent the disease.
Pigmentation and vision: Is GPR143 in control?
  • B. McKay
  • Biology, Medicine
    Journal of neuroscience research
  • 2019
The possibility that this same pathway may intersect with the most common cause of permanent vision loss in the elderly is explored, and a potential way to treat the disease and restore normal retinal development is discussed.


Pharmacokinetics of L-dopa
Differences in the pattern of L-dopa pharmacokinetics in the two groups may explain why the senile-onset group rarely develops ‘wearing-off’, even after long-term L-Dopa therapy, and should be given after meals whenever possible, even if it necessitates a higher L- dopa dose.
Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease
Beneficial effects of amantadine on L‐dopa‐induced dyskinesias in Parkinson's disease
The magnitude of the L‐dopa motor response to oral challenges was not different after amantadine or placebo treatment, and there was no significant reduction of daily off‐time when patients received active treatment, which confirm previous observations concerning the antidyskinetic potential of amantADine.
Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.
300 mg amantadine reduces dyskinesia in Parkinson's disease by approximately 45% but the benefit lasted less than eight months.
Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson's disease.
Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with parkinson's disease
Domperidone therapy significantly reduces upper gastrointestinal symptoms and accelerates gastric emptying of a solid meal, but does not interfere with response to antiparkinsonism treatment.
Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents — preclinical studies
Symptoms of autonomic failure in Parkinson’s disease: prevalence and impact on daily life
It is concluded that autonomic failure is a clinically relevant, pervasive problem in PD and compromise patients’ daily life activities in all stages of the disease.
Gastroparesis and Parkinson's disease: a systematic review.
Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment.